Evaluation of Erlotinib in Advanced Non-Small Cell Lung Cancer: Impact on the Budget of a U.S. Health Insurance Plan

BACKGROUND: Lung cancer is the most common non-skin cancer and the leading cause of cancer death among men and women in North America. More than half of all patients diagnosed with lung cancer are diagnosed with advanced disease. Most cases of lung cancer are non-small cell lung cancer (NSCLC). Erlo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramsey, Scott D., Clarke, Lauren, Kamath, Tripthi V., Lubeck, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2006
Materias:
Formulary Management
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437913/
https://www.ncbi.nlm.nih.gov/pubmed/16925455
http://dx.doi.org/10.18553/jmcp.2006.12.6.472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437913/
https://www.ncbi.nlm.nih.gov/pubmed/16925455
http://dx.doi.org/10.18553/jmcp.2006.12.6.472

Ejemplares similares